Kimmtrak

Tebentafusp, the active ingredient in Kimmtrak, is a bispecific T‑cell engager presented as an intravenous infusion for intravenous administration. It selectively redirects patient T‑cells to gp100 peptide–HLA‑A*02:01 complexes on melanoma cells, leading to T‑cell activation and tumor cell lysis. The therapy is approved for adult patients with metastatic uveal melanoma.

GNH USA supplies Kimmtrak as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and specialty pharmacies worldwide. The company ensures product integrity through validated cold‑chain logistics and provides regulatory documentation to support import and clinical use.

Kimmtrak is a bispecific T‑cell engager used in the treatment of metastatic uveal melanoma.

Metastatic uveal melanoma: improves overall survival and disease control in adult patients with HLA‑A*02:01‑positive tumors.

Kimmtrak may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Infusion‑related reactions such as flushing, chills, or fever - Fatigue or weakness during or after treatment - Nausea, vomiting, or loss of appetite - Skin rash or pruritus

Serious or Rare Side Effects: - Severe cytokine release syndrome, potentially life‑threatening - Cardiac events including arrhythmia or myocarditis - Neurotoxicity presenting as confusion or seizures - Anaphylaxis or severe hypersensitivity reactions - Significant liver enzyme elevations - Hemodynamic instability or hypotension

Before initiating Kimmtrak, clinicians should assess patient suitability and monitor for potential complications. - HLA‑A*02:01 status: confirm positivity before treatment - Cytokine release syndrome: monitor vital signs and laboratory markers during infusion - Cardiac function: evaluate baseline ECG and cardiac history - Infection risk: avoid use in patients with active uncontrolled infections - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Kimmtrak can interact with other agents that modify immune function or affect hemodynamics.

Major Interactions (Avoid): - Concurrent use of other immune checkpoint inhibitors or T‑cell engaging therapies - Live vaccines administered during treatment - Strong immunosuppressants that may blunt therapeutic effect

Moderate Interactions (Monitor Closely): - Anticoagulants or antiplatelet agents due to bleeding risk during infusion - Systemic corticosteroids that could reduce immune activation - Antihistamines that may mask early infusion‑related reactions